Podcasts about Clinical

From horse tranquilizer to mental health treatment — what's the real story about ketamine? Nick Pell breaks it down on Skeptical Sunday!Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we're joined by writer and researcher Nick Pell!Full show notes and resources can be found here: jordanharbinger.com/1241On This Week's Skeptical Sunday:Ketamine therapy shows promise for treatment-resistant depression, PTSD, and chronic pain, but it's serious medicine requiring proper medical supervision, not a recreational escape or wellness trend.Clinical ketamine treatment involves IV administration with precise dosing, vital monitoring, and trained medical attendants — drastically different from recreational use that can cause severe bladder damage and other complications.The rise of telehealth ketamine clinics and mail-order treatments represents a concerning trend — proper vetting requires full psych evaluations, bloodwork, and screening by legitimate medical professionals, not vague promises.Recreational ketamine use carries significant addiction potential and health risks, particularly bladder damage from chronic high doses — clinical settings minimize these dangers through controlled administration.If you're considering ketamine therapy, start with a therapist and real medical doctor. Look for evidence-based treatment with proper intake procedures, not spa-like "optimization centers" making grandiose claims.Connect with Jordan on Twitter, Instagram, and YouTube. If you have something you'd like us to tackle here on Skeptical Sunday, drop Jordan a line at jordan@jordanharbinger.com and let him know!And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors: The Cybersecurity Tapes: Listen here: thecybersecuritytapes.comBiOptimizers: 25% off November 23rd to December 3rd: bioptimizers.com/jordan, code JORDANHomes.com: Find your home: homes.comShopify: 3 months @ $1/month (select plans): shopify.com/jordanApretude: Learn more: Apretude.com or call 1-888-240-0340See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello record from the ASTMH meeting in Toronto and discuss continuing avian flu outbreaks, the continued global measles outbreak, the effectiveness of high and low doses of the influenza vaccine before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, children hospitalizations following COVID-19 and influenza vaccination, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Five new avian flu outbreaks confirmed in ducks, turkeys in 3 US states (CIDRAP) Confirmation of highly pathogenic Avian Influenza in Commercial and Backyard flocks (USDA: Animal and Plant Health Inspection Service) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD) (LANCET) Relative effectiveness of the high-dose versus standard-dose influenza vaccines for the prevention of laboratory-confirmed influenza among Italian older adults during three recent seasons (International Journal of Infectious Diseases) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-word global database (Journal of Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 and influenza deaths in Australian children 2018-2023: a national case analysis (Journal of Pediatric Infectious Diseases Society) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1270 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Ginny Torno, Senior Director, Innovation & IT Clinical Systems at Houston Methodist, sharing how Houston Methodist leverages AI to improve patient outcomes, enhance operational efficiency, and support clinicians while emphasizing strong governance, ROI, and change management in technology adoption.

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:  Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Ibrahim Nawaz Khan joins Ethics Talk to discuss his article, coauthored with Dr Lauren Smith: "What Are Ethical Merits and Drawbacks of a Patient's Open and Direct Access to Clinical Information in Their EHRs During a Hospital Stay?"  Recorded July 30, 2025.  Read the full article for free at JournalOfEthics.org

This episode guides pharmacists through the essentials of pediatric primary and secondary survey assessment, common etiologies of pediatric cardiopulmonary arrest, pediatric advanced life support algorithms for dysrythmias, and provide useful medication tips and management considerations for the clinical pharmacist. CE for this episode expires on November 15, 2027.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This accredited continuing education program is supported by an educational grant from Sanofi. Credit for the program can be obtained by visiting https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-cidp/ . This program, led by Jeffrey Allen, MD, Professor of Neurology at the University of Minnesota provides an overview on the diagnostic delays that often occur in patients with CIDP as well as best practices to suspect and diagnose this rare condition more efficiently. This activity has been designed to meet the educational needs of physicians specializing in family medicine, pediatrics, and neurology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of CIDP.List best practices which can be used to diagnose CIDP more efficiently.Faculty Jeffrey Allen, MDProfessor of NeurologyDepartment of NeurologyDivision of Neuromuscular MedicineUniversity of MinnesotaMinneapolis, MNDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses Consultant/Educational talks: Annexon, Alexion, Amgen, CSL Behring, Takeda,BioCryst, Grifols, Argenx, Sanofi, Immunovant, ImmunoAbs, Octapharma, Alnylam, AstraZeneca, Dianthus, Johnson & Johnson, Laboratoire Français du Fractionnement et des Biotechnologies, Nuvig, Akcea Therapeutics, ImmunoPharma,Pfizer.Community Faculty/Patient (Christine Eleeson): No relevant financial relationships with any ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre-and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Guest Suggestion Form: ⁠⁠⁠⁠⁠https://forms.gle/bnaeY3FpoFU9ZjA47⁠⁠⁠⁠⁠Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are her personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: ⁠⁠⁠⁠⁠https://amzn.eu/d/eCfijRu⁠⁠⁠⁠⁠Order 'Build Don't Talk' (in Hindi) here: ⁠⁠⁠⁠⁠https://amzn.eu/d/4wZISO0⁠⁠⁠⁠⁠Follow Our Whatsapp Channel: ⁠⁠⁠⁠⁠https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2J⁠⁠⁠⁠⁠Subscribe To Our Other YouTube Channels:-⁠⁠⁠⁠⁠https://www.youtube.com/@rajshamaniclips⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@RajShamani.Shorts⁠⁠⁠⁠⁠

En este episodio, exploramos un fenómeno cada vez más inquietante en las consultas y unidades de neurología: el aumento del ictus en adultos jóvenes. A partir de la evidencia más reciente, analizamos cómo los factores de riesgo clásicos están dando paso a nuevos protagonistas del siglo XXI, entre ellos el estrés crónico. Revisamos el papel del ictus criptogénico, las causas vasculares menos conocidas y los mecanismos por los cuales la sobrecarga emocional, laboral o social puede alterar la fisiología cerebrovascular hasta precipitar un evento agudo. También abordamos la diferencia de impacto entre hombres y mujeres, los hallazgos de estudios internacionales como INTERSTROKE y ERICH, y cómo la gestión del estrés debería considerarse una estrategia real de prevención neurológica. Un episodio para reflexionar sobre la relación entre mente, sociedad y cerebro en una generación que vive —y enferma— bajo presión. Referencias del episodio: 1. Behymer, T. P., Sekar, P., Demel, S. L., Aziz, Y. N., Coleman, E. R., Williamson, B. J., Stanton, R. J., Sawyer, R. P., Turner, A. C., Vagal, V. S., Osborne, J., Gilkerson, L. A., Comeau, M. E., Flaherty, M. L., Langefeld, C. D., & Woo, D. (2025). Psychosocial Stress and Risk for Intracerebral Hemorrhage in the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) Study. Journal of the American Heart Association, 14(6), e024457. https://doi.org/10.1161/JAHA.121.024457 (https://pubmed.ncbi.nlm.nih.gov/40055853/). 2. Egido, J. A., Castillo, O., Roig, B., Sanz, I., Herrero, M. R., Garay, M. T., Garcia, A. M., Fuentes, M., & Fernandez, C. (2012). Is psycho-physical stress a risk factor for stroke? A case-control study. Journal of neurology, neurosurgery, and psychiatry, 83(11), 1104–1110. https://doi.org/10.1136/jnnp-2012-302420 (https://pubmed.ncbi.nlm.nih.gov/22930814/). 3. Gutiérrez-Zúñiga, R., Fuentes, B., & Díez-Tejedor, E. (2018). Ictus criptogénico. Un no diagnóstico. Medicina Clínica, 151 (3), 116-122. https://doi.org/10.1016/j.medcli.2018.01.024 (https://www.sciencedirect.com/science/article/abs/pii/S0025775318300770). 4. Khan, M., Wasay, M., O'Donnell, M. J., Iqbal, R., Langhorne, P., Rosengren, A., Damasceno, A., Oguz, A., Lanas, F., Pogosova, N., Alhussain, F., Oveisgharan, S., Czlonkowska, A., Ryglewicz, D., & Yusuf, S. (2023). Risk Factors for Stroke in the Young (18-45 Years): A Case-Control Analysis of INTERSTROKE Data from 32 Countries. Neuroepidemiology, 57(5), 275–283. https://doi.org/10.1159/000530675 (https://pubmed.ncbi.nlm.nih.gov/37231971/). 5. Kutal, S., Tulkki, L. J., Sarkanen, T., Redfors, P., Jood, K., Nordanstig, A., Yeşilot, N., Sezgin, M., Ylikotila, P., Zedde, M., Junttola, U., Fromm, A., Ryliskiene, K., Licenik, R., Ferdinand, P., Jatužis, D., Kõrv, L., Kõrv, J., Pezzini, A., Sinisalo, J., … Martinez-Majander, N. (2025). Association Between Self-Perceived Stress and Cryptogenic Ischemic Stroke in Young Adults: A Case-Control Study. Neurology, 104(6), e213369. https://doi.org/10.1212/WNL.0000000000213369 (https://pubmed.ncbi.nlm.nih.gov/40043226/). 6. Li, W., Zhang, J., Zhang, Y., Shentu, W., Yan, S., Chen, Q., Qiao, S., & Kong, Q. (2025). Clinical research progress on pathogenesis and treatment of Patent Foramen Ovale-associated stroke. Frontiers in neurology, 16, 1512399. https://doi.org/10.3389/fneur.2025.1512399 (https://pubmed.ncbi.nlm.nih.gov/40291846/). 7. Smyth, A., O'Donnell, M., Hankey, G. J., Rangarajan, S., Lopez-Jaramillo, P., Xavier, D., Zhang, H., Canavan, M., Damasceno, A., Langhorne, P., Avezum, A., Pogosova, N., Oguz, A., Yusuf, S., & INTERSTROKE investigators (2022). Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. European heart journal, 43(3), 202–209. https://doi.org/10.1093/eurheartj/ehab738 (https://pubmed.ncbi.nlm.nih.gov/34850877/). 8. Verhoeven, J. I., Fan, B., Broeders, M. J. M., Driessen, C. M. L., Vaartjes, I. C. H., Klijn, C. J. M., & de Leeuw, F. E. (2023). Association of Stroke at Young Age With New Cancer in the Years After Stroke Among Patients in the Netherlands. JAMA network open, 6(3), e235002. https://doi.org/10.1001/jamanetworkopen.2023.5002 (https://pubmed.ncbi.nlm.nih.gov/36976557/). 9. Wegener S. (2022). Triggers of stroke: anger, emotional upset, and heavy physical exertion. New insights from the INTERSTROKE study. European heart journal, 43(3), 210–212. https://doi.org/10.1093/eurheartj/ehab755 (https://pubmed.ncbi.nlm.nih.gov/34850880/). 10. Yaghi, S., Bernstein, R. A., Passman, R., Okin, P. M., & Furie, K. L. (2017). Cryptogenic Stroke: Research and Practice. Circulation research, 120(3), 527–540. https://doi.org/10.1161/CIRCRESAHA.116.308447 (https://pubmed.ncbi.nlm.nih.gov/28154102/). 11. Yang, D., & Elkind, M. S. V. (2023). Current perspectives on the clinical management of cryptogenic stroke. Expert review of neurotherapeutics, 23(3), 213–226. https://doi.org/10.1080/14737175.2023.2192403 (https://pubmed.ncbi.nlm.nih.gov/36934333/).

This week on A Week In Her Wallet, we head to Atlanta to follow Kristen, a 40-something clinical researcher who earns about $150K a year and travels nearly full-time for work. She walks us through a week of thoughtful spending, including a $1,300 mortgage payment, $500 toward her HELOC, a $150 yard sale win (promptly spent on music festival tickets), and the small joys that keep her grounded when she's on the road so much.

John Murray, Ali Bruce-Ball & Conor McNamara talk football, travel & language after Cristiano Ronaldo sees red as Republic of Ireland beat Portugal, and England beat Serbia. What about the ‘mind-altering' shoes some of the England players are wearing? There's a European theme to Clash of the Commentators. And suggestions always welcome for our Great Glossary of Football Commentary and unintended pub names from football commentary - WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk00:40 Conor fresh from Ireland-Portugal 04:40 Takeaways from England-Serbia 06:05 Mind-altering shoes & commentary attire 16:05 5 Live commentaries this weekend 18:00 John prepares for trip to Albania 24:55 Unintended (and intended) pub names 33:15 Clash of the Commentators 41:45 Great Glossary of Football Commentary 52:55 Magazine memories5 Live / BBC Sounds Premier League commentaries: Fri 1945 Slovakia v Northern Ireland on Sports Extra, Sat 1330 Man City v Man Utd in WSL on Sports Extra, Sat 1700 Liechtenstein v Wales on Sports Extra, Sat 1945 Greece v Scotland on 5 Live, Sun 1200 Liverpool v Chelsea in WSL on Sports Extra, Sun 1200 Brighton v Leicester in WSL on Sports Extra 2, Sun 1430 Tottenham v Arsenal in WSL on 5 Live, Sun 1700 Albania v England on 5 Live, Mon 1945 Northern Ireland v Luxembourg on Sports Extra, Tue 1945 Scotland v Denmark on 5 Live, Tue 1945 Wales v North Macedonia on Sports Extra, Wed 2000 Arsenal v Real Madrid in UWCL on 5 Live, Thu 2000 Chelsea v Barcelona in UWCL on 5 Live.Glossary so far (in alphabetical order):DIVISION ONE Bosman, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, Leading the line The Maradona, Olimpico, Onion bag, Panenka, Rabona, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Easy tap-in, Daisycutter, First cab off the rank, Has that in his locker, High wide and not very handsome, Howler, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Nutmeg, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

In this episode, Jason Keeler, President of ReloShare Medical Respite and former COO at UCMC, discusses how early lung nodule detection and collaborative leadership between clinical and administrative teams can improve patient outcomes, streamline care pathways, and strengthen the financial health of healthcare organizations.This episode is sponsored by Noah Medical.

In this episode of MyHeart.net, cardiologist Dr. Alan Bouchard sits down with Dr. Timothy Garvey, Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham, to discuss the evolving definition of obesity as a disease. Drawing from The Lancet's 2025 clinical framework, Dr. Garvey explains when excess adiposity begins to impair organ function, how this redefinition changes patient care, and why understanding obesity as a chronic disease is essential for preventing cardiometabolic complications.About the TeamDr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at UAB Medicine.Dr. Philip Johnson is originally from Selma, AL. Philip began his studies at Vanderbilt University in Nashville, TN, where he double majored in Biomedical and Electrical Engineering. After a year in the “real world” working for his father as a machine design engineer, he went to graduate school at UAB in Birmingham, AL, where he completed a Masters and PhD in Biomedical Engineering before becoming a research assistant professor in Biomedical Engineering. After a short stint in academics, he continued his education at UAB in Medical School, Internal Medicine Residency, and is currently a cardiology fellow in training with a special interest in cardiac electrophysiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast!If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk.The Podcast and the Content are provided on an “as is” basis.

In the past 20 years, the rate of children and teenagers living with high blood pressure globally has nearly doubled because of a toxic combination of unhealthy diets, mass inactivity and soaring levels of obesity. That's according to a new meta analysis of data from 96 studies published in The Lancet Child and Adolescent Health journal. Joining Shane now to discuss this further is the Clinical lead on Obesity for the HSE, Dr Donal O'Shea.

In the past 20 years, the rate of children and teenagers living with high blood pressure globally has nearly doubled because of a toxic combination of unhealthy diets, mass inactivity and soaring levels of obesity. That's according to a new meta analysis of data from 96 studies published in The Lancet Child and Adolescent Health journal. Joining Shane now to discuss this further is the Clinical lead on Obesity for the HSE, Dr Donal O'Shea.

Clinical psychologist Adia Gooden and NPR's It's Been A Minute host, Brittany Luse, answer questions from Dear Life Kit listeners and they share their best advice on unsolicited advice.Follow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekitLearn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of WDx, Cheryl, Kaylin, and Sharmin are joined by Kuchal and Ann Marie, two wonderful members of the CPSolvers Academy.  Kuchal presents a case of a young man with fevers to Ann Marie and Sharmin. Download CPSolvers App here RLRCPSOLVERS

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Ever threaten to take away screen time… only to hand the iPad back 10 minutes later just so you can finish your coffee in peace?

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients. Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed: • The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC. • A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib. • Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity. • Clinical pearls for managing adverse events and optimizing patient care. • The significance of patient education and regular follow-ups in ensuring treatment adherence and safety. Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice! #ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough?In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva's expert in process modeling and sustainability, who's spent years uncovering what really drives emissions and how small process tweaks can deliver big results.Niklas goes beyond the numbers, challenging assumptions and showing how sustainability becomes a strategic, data-driven advantage. From real-world cases at Cytiva, he explains why recycling plastics may not move the needle and why the real gains often lie in hotspots like cleanroom energy use and raw material choices.Here's why this episode will make you rethink your next facility upgrade:Understanding life cycle assessment and the key damage categories in environmental sustainability, including carbon emissions, water usage, and resource depletion. (00:00)The challenge of defining carbon emissions baselines and why it's harder, and often more expensive, to achieve deep reductions if your operations already use clean energy sources. (03:06)Why the focus on recycling single-use plastics may not be the most effective route for lowering emissions, and what truly drives carbon footprint in bioprocessing. (05:54)The impact of production scale, consumables, and obscure chemicals on the overall environmental impact and how these surprises can shift sustainability strategies. (06:20)Practical advice for scientists and engineers: How to start monitoring and modeling environmental impact in process development and manufacturing. (08:00)The importance of involving manufacturing perspectives early in process development, and choosing the right level of detail and ambition for process modeling. (08:18)There's no one-size-fits-all in manufacturing technology—whether fed-batch, continuous, or hybrid and decisions must fit each organization's needs, resources, and ambitions. (10:13)Industry trends that could transform the field, from intensified fed-batch production to future technologies like cell-free expression systems. (11:22)Where to connect with Niklas for further questions or collaboration. (14:03]Whether you're an early-stage startup, a strategic advisor, or on the front lines of bioprocess development, this episode invites you to rethink your sustainability strategy and modeling approach. Check out the below links to connect with Niklas Jungnelius and additional resources.Connect with Niklas Jungnelius:LinkedIn: www.linkedin.com/in/niklas-jungneliusCytiva website: www.cytivalifesciences.com/en/usNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

November 13, 2025 ~ Dr. Chris Shreve, CEO and founder of Dr. Shreve's Clinical, Wellness, and Trauma Center, joins Chris and Lloyd to discuss the Black Men's Mental Health Conference coming to Detroit to bring awareness and education to mental health care for black men. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the RCP Medicine Podcast, Dr Lisa Hamza, HIV and Sexual Health Consultant at St George's Hospital, London, joins Dr Rohan Mehra, Infectious Diseases and Microbiology Registrar, to explore the evolving landscape of HIV care. Together, they delve into the virology, history, and treatment of HIV, highlighting the remarkable progress made over the past four decades - from the early days of the epidemic to today's cutting-edge therapies and prevention strategies.Dr Hamza shares insights from her work as HIV Network Lead in South West London and co-chair of the HIV London Forum, discussing the challenges of stigma, late diagnosis, and health inequalities. The conversation also covers the UK's HIV Action Plan, the impact of opt-out testing, and the promise of long-acting treatments and pre-exposure prophylaxis (PrEP). This episode is a powerful reminder of how far we've come and how much further we must go to reach zero transmissions, zero deaths, and zero stigma.RCP Links Education Events Membership Improving care Policy and campaigns RCP Social Media Instagram LinkedIn Facebook X Bluesky Music: Episode 50 onward - Bensound.com Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas

Join us as we uncover the fascinating role of speech and language therapists working in awake craniotomy. We go to Birmingham to meet SLT Georgie Harrington and Mr Ismail Ughratdar, Consultant neurosurgeon to find out how they work as part of a team. Donald Innes, an expert by experience, who has had two awake craniotomies, shares his story and thoughts about the process. Kathleen Graham, SLT and now senior project manager for the RCSLT and lead on new awake craniotomies position paper (Oct 2025), gives us some of the history about the procedure.With thanks to speakers:Donald Innes, expert by experienceKathleen Graham, Senior Project Manager, Royal College of Speech and Language TherapistsGeorgie Harrington, Clinical lead, Speech and Language Therapy Outpatients, University Hospitals Birmingham NHS Foundation TrustMr Ismail Ughratdar, Consultant Neurosurgeon, Speech and Language Therapy Outpatients, University Hospitals Birmingham NHS Foundation TrustUseful links:RCSLT awake craniotomy position paper (October 2025)Awake craniotomy | RCSLT (resources for the public)Awake craniotomy resources | RCSLT (resources for members of the RCSLT)What to expect during an awake craniotomy for brain tumour removal Please be aware that the views expressed are those of the guests and not the RCSLT.Please do take a few moments to respond to our podcast survey: uk.surveymonkey.com/r/LG5HC3R

In this episode of The Pet Food Science Podcast Show, Dr. Alex German, Professor of Small Animal Medicine at the University of Liverpool, explores how veterinarians and pet nutritionists can better understand and manage obesity in dogs and cats. He explains the clinical definitions of obesity, new prevention strategies, and the future of treatment, including the potential for drug therapies. Discover practical insights to improve companion animal health. Listen now on all major platforms!“Obesity should be recognized as a clinical condition rather than simply excess fat accumulation, as it has direct consequences on health.”Meet the guest: Dr. Alex German is the Professor of Small Animal Medicine at the University of Liverpool. With a veterinary degree and PhD from the University of Bristol, his work focuses on clinical obesity medicine, ageing science, and disease prevention in pets. His research bridges veterinary internal medicine and nutrition, providing essential insights for healthier pets. Liked this one? Don't stop now — Here's what we think you'll love!Don't miss the chance to be part of the Pet Food Inner Circle!Join now and connect with leading experts in pet nutrition: https://petfoodinnercircle.com/What will you learn:(00:00) Highlight(00:54) Introduction(05:24) Obesity classification(11:51) Assessment tools(14:26) Prevention strategies(20:03) Clinical management(23:54) Future therapies(33:56) Final QuestionsThe Pet Food Science Podcast Show is trusted and supported by innovative companies like:* Trouw Nutrition* Kemin- Biorigin

Every few years, conversations about education in the U.S. circle back to the same refrain: Why can't we be more like Finland?In this episode, I sit down with Dr. Chrishawn Finister from Your Joy Psychological, PLLC to unpack this comparison.We dig into the nuanced relationship between educational eligibility and clinical diagnosis, which often overlap but aren't interchangeable. From there, we widen the lens to explore the broader systems-level challenges that shape how students are identified, supported, and served.Some key themes we discuss:✅ Orthographic density and literacy: Why differences in written language systems matter when comparing reading outcomes across countries.✅ Population homogeneity and “education tracks”: When we look at instructional outcomes data, the students included in the education system and the numbers matter. Are the same individuals “counting” when we compare results across countries? ✅ Teacher pay and professional identity: What Finland's investment in teacher preparation and salary looks like compared to the U.S. (spoiler alert: Dr. Finister and I both think the US should be more like Finland on this one). ✅ Cultural perceptions of medicine vs. education: Why recommendations from evaluations are perceived differently depending on the setting and who is making decisions about services.✅ Housing instability and socioeconomic factors: We're educating students with complex needs in the US who have varying experiences outside of school. With this in mind, has the education system made more progress than what the media is saying? Rather than looking for a one-size-fits-all solution, we highlight why U.S. educators, policymakers, and clinicians need to understand the challenges and opportunities when designing systems of support.If you've ever wondered where the lines between clinical diagnosis and educational eligibility blur, this conversation will give you a grounded perspective.Dr. Chrishawn Finister is an Independent Practicing Licensed Psychological Associate and a Licensed Specialist in School Psychology, possessing over a decade of experience in the role of School Psychologist. Recognized as a Nationally Certified School Psychologist, she is committed to utilizing diagnostically sound assessments to identify learning barriers and implementing research-based interventions to amend challenging behaviors effectively. Dr. Finister is an advocate of culturally competent practices and is dedicated to training future practitioners in the field. She received her foundational training in psychological pedagogy and assessments at Texas Woman's University, where she completed her Master's degree in 2010. While working in a prominent North Texas public school district, she advanced her education by earning a Doctoral degree in Educational Leadership and Policy from the University of Texas at Arlington in 2019. Her contributions to the field extend to academia, where she has served as a guest lecturer at the College of Education at Texas Christian University.Places to connect with Dr. Finister:Her private practice, Your Joy Psychological, PLLCWebsite: https://yourjoypsych.com/Business Instagram: @yourjoypsychHer NonProfit, Texas Psychological Hive: https://thetexaspsychhive.org/Non-profit Instagram: @texaxpsychhiveAdditional Resources Mentioned in this episode:Steven Pinker: https://stevenpinker.com/Mark Manson: https://markmanson.net/Dr. Tim Shanahan: https://www.shanahanonliteracy.com/In this episode, I mention Language Therapy Advance Foundations, my program that gives SLPs and other service providers a system for language therapy. You can learn more about the program here: https://drkarenspeech.com/languagetherapy/ We're thrilled to be sponsored by IXL. IXL's comprehensive teaching and learning platform for math, language arts, science, and social studies is accelerating achievement in 95 of the top 100 U.S. school districts. Loved by teachers and backed by independent research from Johns Hopkins University, IXL can help you do the following and more:Simplify and streamline technologySave teachers' timeReliably meet Tier 1 standardsImprove student performance on state assessments

In This Episode:The universal problem of clinical chaos — why your schedule feels brokenThe “wet cement” warning sign that your systems are holding you back5 major scheduling mistakes every chiropractic clinic makes:Letting patients dictate the scheduleBooking errors that crush efficiencyLetting patients “escape the plan”Only booking short-term visits instead of full treatment plansScattered, non-clustered scheduling that destroys flowThe CA/DC partnership: how to create consistency, communication, and authorityBest practices from top-performing clinics:Air Traffic Control (ATC): how to run the adjusting floor like an airport runwayCluster Booking: group adjustments for focus and efficiencyHot Seats: patient-driven flow systems that keep energy highDaily Feedback: how small daily reviews prevent big system breakdownsDr. Lloyd's Power Hour Strategy — the system that lets you serve more patients with less stressHow to calculate and scale your clinic's Maximum Clinical Volume (MCV)Resources Mentioned:

In this episode, I explore the critical role of cellular hydration as the foundational first step in the seven naturopathic steps to treatment to optimise health. Join me as I talk about why proper hydration goes far beyond just drinking water, how chronic dehydration impacts inflammation, hormone balance, and fertility at the cellular level, and the three progressive stages to restoring optimal hydration in your body. I'll unpack the science behind cellular hydration, explain why your cholesterol might actually be a dehydration response, and provide insights and actionable tips to help you build the foundation your body needs to reduce inflammation, support hormone balance, and optimise your fertility journey. A number of actionable tips were discussed including how to recognise signs of chronic dehydration, which foods and drinks are secretly dehydrating you, the proper omega-3 to omega-6 ratio for reducing inflammation, how to implement the three-stage hydration protocol, and why you should consider taking a break from supplements while you establish proper hydration. Episode Highlights: Why hydration is the foundation The 3-Stage Hydration Protocol The seed oil crisis and cell membranes Magnesium—your fertility secret weapon Why your supplements might not be working References: Häussinger D, Roth E, Lang F, Gerok W. Cellular hydration state: an important determinant of protein catabolism in health and disease. Lancet. 1993;341(8856):1330-1332. Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019;40(4):1048-1079. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261-275. Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441-447. Damir HA, Ali MA, Adem MA, et al. The effect of long-term dehydration and subsequent rehydration on markers of inflammation, oxidative stress and apoptosis in the camel kidney. BMC Vet Res. 2020;16(1):437. Doktorova M, Heberle FA, Katsaras J, et al. Dehydration of lipid membranes drives redistribution of cholesterol between lateral domains. J Phys Chem Lett. 2024;15(17):4693-4700. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389-2398. Marziali M, Venza M, Lazzaro S, Lazzaro A, Micossi C, Stolfi VM. Gluten-free diet: a new strategy for management of painful endometriosis related symptoms? Minerva Chir. 2012;67(6):499-504. Calder PC. Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enteral Nutr. 2015;39(1 Suppl):18S-32S. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535-549. >>Endo Fertility Podcast Goodie Bag

if you have any feedback, please send us a text! Thank you!Dr. J.W. Beard, a UCSF-trained anesthesiologist and Chief Medical Officer of GE Healthcare's Patient Care Solutions division, joins the Vital Times podcast to discuss his remarkable career journey. As a member of the Board of the Anesthesia Patient Safety Foundation, Dr. Beard shares how his background in anesthesiology uniquely prepared him for leadership in the medical technology industry, and offers insights into bridging clinical practice and innovation. 

Clinical psychologist Dr. Genesee Herzberg joins Kyle to reflect on two decades in trauma work and 15 years inside the psychedelic ecosystem—from early MAPS conferences to running Sage Integrative Health. She traces how personal psychedelic experiences set her on a path of service, research at CIIS on MDMA-assisted therapy, and hands-on roles with MAPS: Zendo Project harm reduction, adherence rating, and ultimately serving as an MDMA therapist in clinical trials. Today she leads Sage, an integrative clinic (psychotherapy, psychiatry, bodywork, acupuncture, and functional nutrition) focused on ketamine-assisted therapy while preparing for MDMA's eventual approval. She also co-founded a sliding-scale KAP nonprofit (now Alchemy Community Therapy Center), co-edited Integral Psychedelic Therapy, and is helping to launch the International Alliance of MDMA Practitioners. In this episode From counterculture to mainstream: What's been gained—and lost—as psychedelics scaled. Accessibility vs. corporatization: Why cutting corners (prep/integration, therapeutic time) undermines outcomes and safety. "Myth of the magic pill": Psychedelics can catalyze change, but healing is an ongoing process anchored by integration. What good care looks like: Preparation → medicine sessions → robust integration, individualized cadence, and adding bodywork and functional medicine to address gut-brain links, mineral status, sleep, and somatic tension. Ketamine realities: Differences between psycholytic (talk-forward) and psychedelic (eyes-closed, inner-directed) dosing; why some need multiple sessions to build relationship with the medicine; risks of mail-order models (high dosing, poor screening/support), daily prescribing, addiction potential, cystitis, and safety concerns. Sitting, not guiding: The therapist's task is to follow the client's process; intervene sparingly and with consent—especially in trauma work where attuned co-regulation is essential. Multiple access pathways: Support for regulated clinical care and community, peer, and ceremonial models—paired with education and harm reduction (Zendo's SIT peer training and new crisis-responder training). The MDMA pause: Initial devastation at the FDA decision gave way to seeing benefits: time to strengthen ethics, accountability, training standards, and to temper hype-driven investment. Pace and ethics: Lessons from burnout; moving at the speed of trust; exploring "psychedelic business models" (stakeholder focus, distributed decision-making, employee ownership, public benefit structures). Resources & organizations mentioned Sage Integrative Health Alchemy Community Therapy Center (sliding-scale KAP) International Alliance of MDMA Practitioners Integral Psychedelic Therapy (edited by Genesee Herzberg, Jason Butler, Richard Miller) Takeaway: Thoughtful preparation, right-sized dosing, and committed integration—held within ethical, community-minded systems—turn powerful experiences into durable change.

Hosts Zach and Kevin put the sports talk (mostly) aside to dive deep into a critical area of everyday dentistry: various scenarios involving soft and hard tissue grafting and the management of periodontal recession. They discuss how to handle common cases like recession in post-ortho teens (especially on the lower anterior teeth) and the different approaches for the challenging chewing tobacco patient. Zach and Kevin share their experience with generalized recession, debating when to refer for a graft—often noting that patient concern over esthetics or sensitivity drives the decision more than the presence of the recession itself. The conversation covers treatment techniques like free gingival grafts and the status of fads like the LANAP procedure and pinhole technique. They also explore other periodontal topics, including the management of gingival overgrowth (gummy smiles), peri-implantitis complications, and their skepticism regarding the widespread use of local antimicrobial delivery systems (like Arrestin) for routine scaling and root planing cases. Tune in for a candid discussion on what's working (and what's not) in the everyday management of periodontal health in a general practice. Join the Very Clinical Facebook group!  Join the Very Dental Facebook group using the password "Timmerman," "Bioclear," "Hornbrook," McWethy," "Papa Randy," "Lipscomb" or "Gary!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! -- Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYDENTAL10" you'll get another 10% off your order! Go save yourself some money and support the show all at the same time! -- The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! -- Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! -- CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!  

Do This NOW: The 1-Minute Technique to Drop Anxiety & Regulate Your Nervous SystemYour Instant 60-Second Vagus Nerve ResetFeeling a flash of anxiety, emotional overwhelm, or stuck in a loop of overthinking? This short, powerful 1-minute guided session is your immediate tool for nervous system reset and fast stress relief.Clinical hypnotherapist Martin from Calming Anxiety guides you through a simple, yet highly effective somatic technique that takes just 60 seconds to perform.What You Will Learn in 1 Minute:How to use a long, slow out breath (a sighing breath) to speak directly to your vagus nerve.A powerful method to immediately signal safety to your mind.How to feel your core regulate and release built-in tension.This is the perfect emotional regulation tool to use instantly at your desk, before a difficult conversation, or any time you need to drop anxiety fast and carry calm into the next hour.For Deeper Calm: If you need deeper somatic healing or more extended emotional regulation tools, subscribe to Calming Anxiety.Support the Show:Ad-Free Listening: Enjoy Calming Anxiety without ads at https://www.spreaker.com/podcast/calming-anxiety--4110266/supportBuy Me a Coffee: Support hosting costs at https://www.buymeacoffee.com/calminganxietyRate & Review: Leave a 5-star review on Spotify or Apple Podcasts to help us reach more listeners!Resources & Courses:Book Hypnotherapy: Schedule a one-on-one session with Martin at https://calendar.app.google/rXHMt8sRYft5iWma8 Pain & Anxiety Course:Manage negative thoughts and pain with The Physio Crew's course at https://offers.thephysiocrew.co.uk/home-painBreathing Challenge: Try our relaxing breathing challenge at https://www.martinhewlett.co.uk/breathing-challenge/Gift a Subscription: Share Calming Anxiety with loved ones at https://www.martinhewlett.co.uk/shop/calming-anxiety-gift-subscription/Get the App:iOS: Download Calming Anxiety at https://apps.apple.com/gb/app/calming-anxiety/id1576159331 Android:Get it on Google Play at https://play.google.com/store/apps/details?id=digital.waterfront.calming.anxiety&hl=en-GBConnect With Us:Email: Share feedback or requests at calminganxiety@martinhewlett.co.ukYouTube: Watch all episodes at https://www.youtube.com/c/calminganxiety?sub_confirmation=1 Social Media Support: For younger listeners struggling with social media stress, visit https://www.icanhelp.net/Backing Music: Chris Collins===================Affiliate links to the gear I use the items that give me a more tranquil life.Rode Podmic - https://amzn.to/3LN1JEdZoom Livetrak L8 - https://amzn.to/36UCIbySony ZV 1 - https://amzn.to/3JvDUPTGoPro Hero 8 Black - https://amzn.to/372rzFlDJI Mini 2 - https://amzn.to/3NQfMdY=============================Items I use for a more relaxed way of life :)Organic Pure Hemp CBD Capsules - https://amzn.to/3Ready for More Calm?Thank you for listening to the Calming Anxiety Podcast, featuring guided meditation, mindfulness, and sleep hypnosis sessions with Martin Hewlett. Our mission is to provide you with proven tools for anxiety relief, stress reduction, and a path toward deep relaxation. Use this episode anytime you need to calm your mind and feel more at ease.

In this episode of the Dental Boardroom Podcast, host Wes Read, CPA and financial advisor at Practice CFO, sits down with Howard Farran, founder of Dentaltown and one of the most influential thought leaders in the dental industry. Together, they explore the evolution of dentistry from emerging AI technology to the rise of DSOs, the challenges new grads face, and the skills needed to thrive in today's rapidly shifting landscape. This episode delivers raw insights, bold perspectives, and practical lessons for dentists at every stage of their careers.Key PointsAI & the Future of DentistryAI is transforming dentistry at historic speed—comparable to the rise of the internet.Dentaltown is building AI tools to unlock insights from 10+ million dental conversations.AI won't replace dentists but dentists who adopt AI will replace those who don't.Example: Robotics like Yomi are enhancing implant surgery, not eliminating the surgeon.The Real DSO LandscapeNot all DSOs are massive corporate chains.The real competition for private practices? Local 4–9 location DSOs scaling smartly across small regions.These local groups win by leveraging:Shared marketingCentralized operationsBetter purchasing powerStructured systemsAdvice for Young DentistsStudent debt is real, but so are lifestyle choices that amplify it.Early career focus should be:Clinical reps and speedLearning practice systemsStrong mentorshipThe best first job is one that teaches:Business operationsFull-scope clinical carePatient flow and case acceptanceThe Competitive Edge for Private PracticePatients choose loyalty, trust, and relationships.Private practices win when they deliver:Consistency in careStable teamsReal human connectionHigh staff and doctor turnover in corporate settings creates opportunities for private offices to stand out.Know Your Numbers With the Right AdvisorA general accountant isn't enough in dentistry.Dentists need advisors who understand:PPO strategyOverhead benchmarksPractice-specific financial planningGrowth vs. profitabilitySpecialized financial guidance is a competitive advantage.Insurance is Not the Whole MarketHalf of patients don't have dental insurance.Present multiple treatment paths:Basic → Mid-tier → Ideal careNever assume what a patient can or can't afford—let them choose.Who Should Listen?✔ New dentists navigating debt and career choices ✔ Private practice owners competing with DSOs ✔ Clinicians curious about AI adoption ✔ Anyone wanting unfiltered industry truth

This episode (#306) addresses a common but painful question from betrayed partners: “Is my spouse a narcissist, or just showing narcissistic tendencies?” Mark and Steve explain that while the term “narcissist” has become a cultural buzzword, true narcissistic personality disorder (NPD) is rare and defined by a complete absence of empathy. In contrast, addicts in denial often appear narcissistic because they're reacting defensively from fear and shame. Their hurtful behaviors—blame-shifting, gaslighting, and emotional withdrawal—mimic narcissism but stem from self-protection, not superiority.The hosts emphasize that what matters most isn't the label but the destination. Whether the issue is narcissism, addiction, or emotional immaturity, the key question is: Where is this relationship heading if nothing changes? The described situation clearly reflects an abuse cycle—one fueled by denial, volatility, and manipulation. For the addict, breaking that cycle means pausing reactivity, taking full ownership, and seeking specialized recovery help rather than generic therapy. True healing begins only when defensiveness gives way to empathy and accountability.For the betrayed partner, safety and support come first. Isolation only deepens the trauma, so finding community through trusted friends, family, or support groups like S-Anon and SALifeline is essential. She must set firm boundaries and remember that protecting her partner from consequences is not the same as loving him. The episode closes with practical resources—including books like The Gaslighting Recovery Workbook and Adult Children of Emotionally Immature Parents—and a hopeful reminder that even deeply wounded couples can rebuild when they both commit to truth, humility, and genuine change.For a full transcript of this podcast in article format, go to:   Is My Partner a "Narcissist" of does he just have Narcissistic Tendencies?Learn more about Mark and Steve's revolutionary online porn/sexual addiction recovery and betrayal trauma healing program at—daretoconnectnow.comFind out more about Steve Moore at:  Ascension CounselingLearn more about Mark Kastleman at:  Reclaim Counseling Services

Your Manufacturing Decisions Are Costing You More Than You ThinkEvery bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash.The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framework that reveals exactly where your money goes and why.In this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Niklas Jungnelius, Process Modeling Leader at Cytiva, who has spent 25+ years decoding the economics of biologics manufacturing for biotech companies navigating billion-dollar decisions.Niklas reveals the hidden cost drivers most teams miss, the surprising economics behind fed-batch vs. continuous processing, and why your facility choice at intermediate scale could make or break your business case.Episode Highlights:What process economic modeling is and how it differs from mechanistic modeling (06:40)Main cost drivers in biologics and biosimilars manufacturing, and their direct and indirect impacts on patient pricing (09:21)The role of manufacturing scale and productivity in driving down costs, and how facility type (stainless steel vs single-use) affects labor, flexibility, and investment (11:51)Trade-offs between single-use and stainless steel facilities at intermediate production scales (15:07)Key differences in cost and efficiency between fed-batch and fully continuous manufacturing, including productivity limitations and capital/expenditure implications (16:20)The impact of resin lifetime and under-utilization on clinical manufacturing costs (19:51)Hidden or less quantifiable costs such as facility flexibility, excess capacity, safety margins, and the importance of realistic assumptions in economic modeling (20:20)This is a grounded discussion with practical takeaways for biotech scientists seeking clarity in the complex terrain of process economics. Part two of this conversation will focus on sustainability modeling and the latest technologies reshaping bioprocessing economics.Ready to see how process modeling could transform your approach and protect your bottom line? Listen to the episode and rethink your next investment.Connect with Niklas Jungnelius:LinkedIn: www.linkedin.com/in/niklas-jungneliusCytiva website: www.cytivalifesciences.com/en/usNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Microsoft recently launched Dragon Copilot, a next-generation AI clinical assistant designed to transform how clinicians manage time-consuming administrative tasks - from documentation and referrals to after-visit summaries. By streamlining workflows and integrating seamlessly with electronic patient records (EPRs), it frees up valuable time for what matters most: patient care.The technology combines fine-tuned generative AI with Dragon Medical One's speech capabilities and the ambient AI of Dragon Ambient eXperience (DAX). It comes at a time when a Microsoft-commissioned report revealed that 40% of patients have experienced consultations where clinicians appeared too focused on their screens to fully engage. To find out more about Dragon Copilot I spoke to Dr Simon Wallace, Chief Clinical Information Officer at Microsoft UK and Ireland.Dr Wallace talks about his background, what Dragon Copilot does, the benefits of using Dragon Copilot and more.More about Dr Simon Wallace:Dr Simon Wallace is a medical doctor specialising in GP, hospital, and public health care with over 20 years of experience in healthcare transformation. He currently serves as the Chief Medical Information Officer (CMIO) and Director of Business Strategy for Microsoft UK & Ireland, where he leads the integration of health-tech innovations—especially AI and conversational systems—into clinical workflows.

Overview: In this episode, Dr Melissa Jones and Dr Christian Ramers discuss the importance of pan-viral screening for HIV and hepatitis. They emphasize the need for integrated testing and prevention strategies and the current barriers to implementation. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Christian B Ramers, MD, MPH, FIDSA, AAHIVS; Melissa Jones, DNP, APRN-BC   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2025. Available from: https://www.hcvguidelines.org/ (Accessed June 10, 2025). Arora DR et al. ISRN AIDS 2013;2013:287269 Alter MJ. J Hepatol 2006;44:S6–9. Bazargan M, Cobb BMS, Assari S. Ann Fam Med 2021;19:4–15. Beard N, Hill A. Open Forum Infect Dis 2024;11:ofad666. Bottero J, Boyd A, Gozlan J et al. Open Forum Infect Dis 2015;2:ofv162. Brunetto, Maurizia Rossana et al. J Hepatol 2023;79:433–60. Calabrese SK, Krakower DS, Mayer KH. Am J Public Health 2017;107:1883–89. CDC. Status neutral HIV care and service delivery eliminating stigma and reducing health disparities. 2022. Available from: https://stacks.cdc.gov/view/cdc/129024 (Accessed June 10, 2025). CDC. Clinical guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 10, 2025). CDC. Clinical screening and diagnosis for hepatitis C. 2025. Available from: https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing (Accessed June 10, 2025). CDC. Clinical testing and diagnosis for hepatitis B. 2025. Available from: https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/  (Accessed June 10, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 10, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/ (Accessed June 10, 2025). CDC. Hepatitis A vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-a/vaccination/index.html (Accessed June 10, 2025). CDC. Hepatitis B vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-b/vaccination/index.html (Accessed June 10, 2025). CDC. HIV infection among heterosexuals at increased risk--United States, 2010. MMWR Morb Mortal Wkly Rep 2013;62:183-8. CDC. Viral hepatitis among people with HIV. 2025. Available from: https://www.cdc.gov/hepatitis/hcp/populations-settings/hiv.html (Accessed June 10, 2025. Clinical info HIV.gov. Considerations for Antiretroviral Use in People With Coinfections, Hepatitis B Virus/HIV Coinfection. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/hepatitis-b-virus-hiv-coinfection (Accessed July 21, 2025). Cornberg M, Sandmann L, Jaroszewicz J et al. J Hepatol 2025; doi: 10.1016/j.jhep.2025.03.018. Coukan F, Murray KK, Papageorgiou V et al. HIV Med 2023;24:893–913. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). GHTF. Breaking the silence: combating stigma and misinformation in the fight against hepatitis. 2024. Available from: https://www.globalhep.org/news-blogs/breaking-silence-combating-stigma-and-misinformation-fight-against-hepatitis (Accessed June 10, 2025) Grieb SM, Harris R, Rosecrans A et al. Ann Med 2022;54:138–49. HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 10, 2025). Kitt H et al. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. 2024. Available from https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report (Accessed June 10, 2025) Mayer KH, Agwu A, Malebranche D. Adv Ther 2020;37:1778–811. Mohareb AM, Larmarange J, Kim AY et al. Lancet HIV 2022;9:e585–e94. Moorman AC, Bixler D, Teshale EH et al. Public Health Rep 2023; doi: 10.1177/00333549231181348 Orkin, C. Open Forum Infect Dis 2024;11:ofad668. Post Z et al. Clin Liver Dis 2023;27:973-84 Saleska JL, Lee SJ. JAMA Pediatr 2020;174:1133–34. Symum H, Van Handel M, Sandul A et al. Prev Med Rep 2024;44:102777. UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2025. Available from: https://www.unaids.org/en/resources/fact-sheet (Accessed July 18, 2025). UNM. Project ECHO. 2025. Available from: https://projectecho.unm.edu/ (Accessed June 10, 2025). Wejnert C et al. MMWR Morb Mortal Wkly Rep. 2016;65:1336–1342 WHO. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations (Geneva). 2022. Available from: https://www.who.int/publications/i/item/9789240052390 (Accessed June 10, 2025). WHO. Fact sheet: hepatitis A. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a (Accessed June 10, 2025). WHO. Fact sheet: hepatitis B. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (Accessed July 18, 2025). WHO. Fact sheet: hepatitis D. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d (Accessed June 10, 2025). WHO. Guidelines on HIV self-testing and partner notification: a supplement to the consolidated guidelines on HIV testing services. 2016. Available from: https://iris.who.int/handle/10665/251655 (Accessed June 10, 2025). WHO. Recommendations and guidance on hepatitis C virus self-testing. 2021. Available from: https://www.who.int/publications/i/item/9789240031128 (Accessed June 10, 2025). Xiao Y et al. Cells. 2020;9:2233

Overview: In this episode, Toyin Nwafor, MD, and Christian B Ramers, MD, draw on their experience in primary care, HIV and HIV prevention to highlight missed opportunities for HIV prevention and discuss strategies to help address gaps in the HIV care continuum. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Christian B Ramers, MD, MPH, FIDSA, AAHIVS   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AIDSVu.org. Prevalence in the United States. 2022. Available from: https://map.aidsvu.org/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Discussing sexual health with your patients. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/sexual-history/index.html (Accessed June 25, 2025). CDC.gov. HIV diagnoses, deaths, and prevalence. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 update: a clinical practice guideline. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Doblecki-Lewis S et al. J Int Assoc Provid AIDS Care 2019;18:2325958219848848. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed May 21, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed July 18, 2025). HIV.gov. Who is at risk for HIV. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/who-is-at-risk-for-hiv (Accessed June 25, 2025). Johns Hopkins Bloomberg School of Public Health. What to know about PrEP. 2025. Available from: https://publichealth.jhu.edu/2025/who-needs-prep-for-hiv-prevention (Accessed June 25, 2025). Kamis KF et al. Open Forum Infect Dis 2019;6:ofz310. KFF. HIV testing in the United States. 2024. Available from: https://www.kff.org/hiv-aids/hiv-testing-in-the-united-states/ting in the United States | KFF (Accessed August 26, 2025). NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-infections-stis (Accessed June 25, 2025). Ramchandani MS et al. Curr HIV/AIDS Rep 2019;16:244–56. Saag MS et al. JAMA 2018;320:379–96. Sweeney P et al. J Acquir Immune Defic Syndr 2019;82(Suppl 1):S1–5. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). UNAIDS.org. Recommended 2030 targets for HIV. 2025. Available from: https://www.unaids.org/en/recommended-2030-targets-for-hiv (Accessed August 26, 2025). United States Census Bureau. National population by characteristics: 2020-2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025). United States Census Bureau. United States Population Growth by Region. 2025. Available from: https://www.census.gov/popclock/ (Accessed June 25, 2025). Yumori C et al. Sex Transm Dis 2021;48:32–6.

Overview: In this episode, Dr Toyin Nwafor and Dr Andrew Zolopa provide an overview of the HIV treatment landscape both globally and in the United States. They highlight the current gaps in the HIV care continuum, emphasize the importance of rapid start and viral suppression in reducing HIV transmission through sex and describe initiatives and strategies aimed at closing these gaps to help end the HIV epidemic in the United States. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Andrew Zolopa, MD   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AETC. Rapid (immediate) ART initiation and restart: guide for clinicians. 2023. Available from: https://aidsetc.org/resource/rapid-immediate-art-initiation-restart-guide-clinicians (Accessed June 25, 2025). Baxter A et al. J Acquir Immune Defic Syndr 2025;99:47–54. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 25, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/index.html#cdc_testing_why_get_tested-why-get-tested (Accessed June 25, 2025). CDC. Laboratory testing for the diagnosis of HIV infection. 2014. Available from: https://stacks.cdc.gov/view/cdc/23446 (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). Delaney KP et al. Am J Prev Med 2021;61(5 Suppl 1):S6–S15. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. EHE overview. 2025. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview (Accessed June 25, 2025). HIV.gov. Global statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (Accessed June 25, 2025). HIV.gov. HIV Care Continuum. 2025. Available from: https://www.hiv.gov/federal-response/other-topics/hiv-aids-care-continuum (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 25, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed June 25, 2025). Mirzazadeh A et al. PLoS Med 2022;19:e1003940. NIH. HIV testing. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-testing (Accessed June 25, 2025). Palacio-Vieira J et al. BMC Public Health 2021;21:1596. Saag MS et al. JAMA 2018;320:379–96. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). WHO. Supporting re-engagement in HIV treatment services: policy brief. 2024. Available from: https://www.who.int/publications/i/item/9789240097339 (Accessed June 25, 2025).

Join George Hariri and Richard Low as they dive into the real-world applications of AI in dental practice management. From co-diagnosis tools and automated SOP creation to marketing insights and team performance reviews, they explore how dentists can harness AI today—and what's just around the corner.

Send us a textJoin Dr. Daphna Yasova Barbeau as she kicks off The Incubator's live coverage from the Children's Hospitals Neonatal Consortium (CHNC) 2025 Symposium in Denver. This opening episode sets the stage for two days of conversations focused on improving care for high-risk infants through data sharing, collaboration, and quality improvement across Level IV NICUs. Daphna introduces the mission behind CHNC and its powerful Children's Hospitals Neonatal Database (CHND)—a resource driving benchmarking and innovation nationwide. Tune in for context, purpose, and the energy that fuels this year's meeting before diving into interviews with CHNC leaders and attendeesSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Welcome to another episode of the Sustainable Clinical Medicine Podcast! In this episode, Dr. Sarah Smith sits down with Dr. Cheryl Chase, a clinical psychologist and expert in attention and learning disorders, to explore the unique challenges clinicians face in making their workday more sustainable. Dr. Chase shares her journey from working with children to advising physicians and other adults, highlighting practical strategies for maintaining executive function, managing overwhelming administrative tasks like charting, and coping with burnout and decision fatigue. The conversation dives deep into how both neurodiverse and neurotypical clinicians can adopt simple, habit-based solutions to tackle the ever-growing workload, find ways to set boundaries, and build systems that truly support wellbeing—inside and outside the clinic. Whether it's accepting that perfection is unattainable, learning to disappoint others when necessary, or using visual tools and external reminders to stay organized, Dr. Chase brings relatable wisdom and actionable advice to help listeners preserve their energy and get home with their work done. If you've ever wondered how to start tackling that painful chart backlog, keep your executive function sharp throughout the day, or simply give yourself more grace at work, you're in the right place. Get ready for a thoughtful, empowering discussion packed with ideas you can put into practice today. Here are 3 key takeaways from this episode: Habits Beat Willpower: Whether it's charting, managing emails, or tackling that overwhelming to-do pile, consistent habits and small rewards can make all the difference. Set up simple, repeatable systems to take the edge off tasks you hate—pair a reward with every chart completed, or celebrate reaching micro-goals. Radical Acceptance & Boundaries: It's okay (and necessary) to get comfortable disappointing others. You can't (and shouldn't) say yes to everything—prioritize your energy for the things and people that matter most. Set clear boundaries for email, patient messages, and team interruptions. Support Your Executive Function: Fatigue and burnout are real. Proactively support your brainpower with quality sleep, mindful breaks, minimal task switching, and templates to reduce decision fatigue. Even short, timed bursts of focused work can move you forward! Meet Dr. Cheryl Chase: Dr. Cheryl Chase is a licensed clinical psychologist based in Independence, Ohio (a suburb of Cleveland), specializing in ADHD, learning disorders, and emotional challenges across the lifespan. Through PSYPACT, she is able to serve clients in over 42 states in the US. She's also an international speaker and consultant, known for making complex topics like executive function and dyslexia both relatable and actionable. Whether she's working with families, schools, or businesses, Dr. Chase blends science with real-world strategies—and a dose of humor. -------------- Would you like to view a transcript of this episode? Click Here **** Charting Champions is a premiere, lifetime access Physician only program that is helping Physicians get home with today's work done. All the proven tools, support and community you need to create time for your life outside of medicine. Learn more at https://www.chartingcoach.ca **** Enjoying this podcast? Please share it with someone who would benefit. Also, don't forget to hit “follow” so you get all the new episodes as soon as they are released. **** Come hang out with me on Facebook or Instagram. Follow me @chartingcoach to get more practical tools to help you create sustainable clinical medicine in your life. **** Questions? Comments? Want to share how this podcast has helped you? Shoot me an email at admin@reachcareercoaching.ca. I would love to hear from you.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.The large and growing field of specialty pharmacy means new opportunities and challenges for ensuring patients receive the specialty drugs they need and stay on the therapies that might save their lives. St. Luke's Health System, based in Boise, Idaho, has approached this mission by embedding clinical pharmacists in the specialty pharmacy space and using 340B as a critical tool. We speak with Josh Weber, senior director of ambulatory retail and specialty pharmacy services at St. Luke's, to learn more.How Clinical Pharmacists Can Be a “Value Multiplier”Embedding clinical pharmacists in their specialty pharmacies improves operations in myriad ways. These pharmacists can take the burden off other providers by meeting with patients to go over their drug regimens, coordinating care, and running split-fill programs to reduce waste. At St. Luke's, the approach has improved patient adherence to medications and reduced the time between the specialty prescription and the patient having the medication in hand to less than 48 hours – far quicker than the industry standard.340B Savings Are Key to the InvestmentWeber says cost savings from 340B are critical in calculating how they embed resources into specialty pharmacy, noting that improving adherence and retention can increase 340B savings exponentially. These savings then can enable health systems such as St. Luke's to reinvest in their internal specialty pharmacies, provide more patient cost assistance and unreimbursed care, and ultimately shield themselves from headwinds such as drugmaker contract pharmacy restrictions.Embedding Pharmacists Depends on Hospital-Specific FactorsFor hospitals considering following the lead of St. Luke's Health System, Weber said a variety of factors such as patient volume, payer mix, and drug spend can call for a variety of service models and investment strategies. Harnessing data such as heat maps showing where patients are and which clinics they visit can inform how best to embed pharmacists and ultimately improve specialty pharmacy care for patients.Resources:Drugmakers Release 340B Rebate Pilot Program DescriptionsHRSA 340B Rebate Model Pilot ProgramBeacon Rebate Model Resources

About this Episode Episode 50 of “The 2 View” – BNPs, D-Dimers, and Sneakily Sick Kids Segment 1A - Needs of older nurses Clendon JA, Walker L. Nurses aged over 50 and their perceptions of flexible working: The experiences and needs of older nurses in relation to flexible working and the barriers and facilitators to implementation within workplaces. J Nurs Manag. 2016;24:336-346. doi:10.1111/jonm.12325 Segment 1B - WHO and Tropical Diseases Special Programme for Research and Training in Tropical Diseases. World Health Organization. Accessed August 19, 2025. https://tdr.who.int/about-us Segment 2A - BNP Silvers SM, Gemme SR, Hickey S, et al. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Heart Failure Syndromes. Ann Emerg Med. 2019;49(2): 232–241. Lamberta M, Chertoff A. BNP Level in the Emergency Department: Does it Change Management? EMDocs. June 20, 2016. Accessed November 4, 2025. https://www.emdocs.net/bnp-level-in-the-emergency-department-does-it-change-management/ Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi: 10.1056/NEJMoa020233 Segment 2B - D-Dimer Wolf SJ, Hahn SA, Nentwich LM, et al. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected acute venous thromboembolic disease. Ann Emerg Med. 2018;71(5):e59–e109. doi:10.1016/j.annemergmed.2018.03.006 Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA. 2014;311(11):1117–1124. doi:10.1001/jama.2014.2135 van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): A prospective, multicentre, cohort study. Lancet. 2017;390(10091):289–297. doi:10.1016/S0140-6736(17)30885-1 Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125–2134. doi:10.1056/NEJMoa1909159 Lim w, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-3256. doi:10.1182/bloodadvances.2018024828 Kabrhel C, Jaff MR, Channick RN. D-dimer. StatPearls. June 22, 2025. Accessed November 4, 2025. https://www.ncbi.nlm.nih.gov/books/NBK431064/ Tripodi A, Lippi G. How we manage a high D-dimer. Haematologica. 2020;106(6):1491-1494. doi:10.3324/haematol.2020.248344 Segment 3: Sneakily Sick Kids Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: An evidence-based clinical prediction algorithm. J Bone Joint Surg Am. 1999;81(12):1662-1670. doi:10.2106/00004623-199912000-00002 Caird MS, Flynn JM, Leung YL, et al. Factors distinguishing septic arthritis from transient synovitis of the hip in children: a prospective study. J Bone Joint Surg Am. 2006;88(6): 1251-1257. doi:10.2106/JBJS.E.00216 Recurring Sources Center for Medical Education. http://ccme.org The Proceduralist. http://www.theproceduralist.org The Procedural Pause. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. http://www.thesgem.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to.

Fitt Insider: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- Today, I'm joined by Jared Pobre, founder & CEO of Caldera + Lab.   Launched in 2019, Caldera + Lab is revamping men's medicine cabinets with proprietary premium skincare formulas specifically engineered for guys.   In this episode, we discuss building a biotech-driven men's personal care brand.   We also cover:   Targeting the longevity-minded male consumer Prioritizing proprietary R&D over repurposed formulas Developing distribution strategies and hospitality partnerships   Subscribe to the podcast → insider.fitt.co/podcastSubscribe to our newsletter → insider.fitt.co/subscribeFollow us on LinkedIn → linkedin.com/company/fittinsider Caldera + Lab's Website: www.calderalab.com  Amazon: https://www.amazon.com/stores/CalderaLab/page/2A608586-7E58-411C-8057-FFD688968227   -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart workout solutions for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (01:08) Jared's background and Caldera + Lab overview (01:33) The evolution of men's skincare since 2016 (03:02) Formulation differences: women's vs. men's skincare (04:32) Custom formulations vs. menu-based co-manufacturing (06:24) Pioneering proprietary ingredients for men (08:00) Building the brand with bootstrapped resources (10:30) Clinical studies and efficacy testing (13:00) Customer acquisition and finding product-market fit (15:30) DTC and Amazon as core distribution channels (17:45) Storytelling and messaging strategy (21:53) Balancing scientific credibility with consumer messaging (23:12) Targeting the longevity-minded male consumer (25:11) Retail expansion strategy and Series A funding (26:15) Country clubs, luxury hotels, and hospitality partnerships (27:26) Product roadmap (28:49) Conclusion  

This episode dives into the complex and often misunderstood MedTech market in China, featuring Elaine Tan, creator of MedTech Chopsticks, who translates the nation's stringent regulatory language into actionable insights. Elaine and host Etienne Nichols discuss the substantial risks and rewards of bringing a medical device to China, highlighting the country's rapid execution, intense internal competition, and the shift from low-end manufacturing to a focus on high-level innovation. A key risk is that existing international certifications (like ISO and IEC) do not guarantee compliance, requiring local type testing and adherence to specific national standards.The conversation addresses how global medical device companies can structure their strategy amid ongoing geopolitical shifts and the "China for China" policy, which favors domestic products through initiatives like the Volume-Based Procurement (VBP). Strategies such as the dual-strategy approach—localizing low-consumable manufacturing while protecting high-technology IP through joint ventures or careful CMO/CDMO selection—are explored as pragmatic ways to secure market presence and margin. Understanding the regulatory landscape, particularly the NMPA's 2021 overhaul, is crucial for success.Finally, Elaine provides practical guidance for regulatory professionals intimidated by the market. This includes understanding the specific regulatory and clinical pathways, performing a gap analysis against Chinese standards (Product Technical Requirements or PTR), and the critical process of selecting and qualifying a local partner/agent. Elaine reveals a specific, often overlooked hurdle: the agent must possess an NMPA-approved CA (Certification Authorization) USB key to electronically submit registration files on behalf of the foreign manufacturer, a critical piece of the submission puzzle. The discussion also touches on leveraging special zones, like the Hainan Free Trade Zone, for crucial real-world data collection applicable to the Chinese population.Key Timestamps[02:40] Introduction to Elaine Tan, MedTech Chopsticks, and the show's focus on the China market.[05:05] High-level risks and rewards: complexity, lengthy registration, local testing requirements, and IP concerns.[08:08] Discussing the NMPA's 2021 regulatory overhaul and the geopolitical shift toward "China for China."[11:00] The Dual Strategy approach: balancing low-end localization with protecting high-tech IP.[14:48] Using CDMOs/CMOs for pilot projects to manage financial investment risk.[16:20] Leveraging the Hainan Free Trade Zone (Bo'ao region) for pre-market clinical data collection and urgent needs product access.[18:42] Ethological differences and their impact on clinical data justification (e.g., Pulse Oximeters).[20:17] NMPA predicate search: The importance of using the Chinese Classification Catalog to find registered, local predicate devices.[23:00] Guidance for overwhelmed regulatory professionals entering the China market: Clinical strategy and Product Technical Requirements (PTR).[25:52] Pitfalls in partner selection: The necessity of the NMPA-approved CA (Certification Authorization) USB key for submissions.[29:30] Partner qualification: Ensuring the agent can support Post-Market Surveillance (PMS) and QMS self-inspection requirements.[30:52] Final pitfall: International compliance (ISO/IEC) does not automatically ensure China...

Sunday, November 9, 2025. Week 46.   End of year campaign: UNLOCK THEIR TOMORROW, curesyngap1.org/unlock    Why now? UNLOCK It's giving season. Count our blessings and share what we have.  CS1 has moved mountains this year: Staff, ProMMiS, etc. But we are just starting…   Every single family should give and should solicit their friends.  Yes, it's a tough time.  Yes, people have other causes.  No (most of) your friends don't have a SynGAPian.   Miss 100% of the shots you don't take.  And remember, donors learn about what they give to, so even small donations cause huge changes in awareness.   Go to our Champions page: https://curesyngap1.org/champions-of-hope/ Tony, Myla, Hattie, Jansen, Kai, Sophia, Kaylie, Gracie are at $50k+.  Eight families.  It's only five at $100k+.  I think we can do better.  I also think we should have more participation at every level, we can't lean on a handful of families to carry this organization.   These families get something key: CURE SYNGAP1 is in it for the long run, unlike EVERYONE ELSE you are supporting.  Great that you are doing schools, horses, girl scouts, etc, but the only people asking you for money right now that are going to be fighting for your kid in 5, 10, or 50 years, is CURE SYNGAP1.  The only group who won't kick your family/loved one out of our community when your SynGAPian bites one of our staff or elopes from a meeting across streets.  Also us.  The people who understand SYNGAP1 the best.  Right here.   Technicals, we could not make this easier!   Take 5 minutes to build your own fundraiser or simply email friends/family/co-workers/church associates/other kids' sports team parents/etc. It's uncomfortable but essential.    It's so darn easy to give - 

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses the link between in utero SARS-CoV-2 infection and poor neurodevelopment outcomes, the use of an mRNA vaccine as an anti-cancer therapy, why one should receive the HPV vaccine, asymptomatic H5N1 isolations in humans, and H5N1 on turkey farms, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how two vaccinated physicians became infected with measles, effective of COVID-19 vaccine for children, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how a specific antibody type may associate with recovery from long COVID, if use of a probiotic is helpful to treat mild COVID-19, if vaccination helps prevent long in adolescents and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Neurodevelopmental Outcomes of 3-Year-Old Children Exposed to Maternal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Utero (Obstetrics & Gynecology) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1267: A cancer vaccine and an mpox treatment (microbeTV: TWiV1267) Cancers Caused by HPV (CDC: Human papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendation (CDC: Vaccines & Immunizations) Asymptomatic Human Infections With Avian Influenza A(H5N1) Virus Confirmed by Molecular and Serologic Testing (JAMA: OPEN Network) Review: Human H5N1 avian flu cases can be asymptomatic, and the virus likely spreads among people (CIDRAP) Avian flu strikes turkey farms in Dakotas, large egg facility in California (CIDRAP) Another Doctor at Ichilov Contracts Measles After Treating Unvaccinated Child (gov.il) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England (LANCET: Child & Adolescent Health) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019–Associated Hospitalization (CID) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID (Journal of Infection) Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19 (Infectious Diseases and Therapy) Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection (Vaccine) Reaching out to US house representative Letters read on TWiV 1268 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.